Eukaryotic DNA is packaged with histone proteins to form nucleosomes, which in turn condense into higher-ordered structures that constitute the different functional forms of chromatin. It is well accepted that chromatin structural states such as heterochromatin (highly condensed/ transcriptionally inactive) or euchromatin (decondensed/ transcriptionally active), can be propagated in an epigenetic fashion (i.e. associated with heritable changes in phenotype that are not related to changes in DNA sequence). Importantly, mis-regulation of chromatin structure and posttranslational modifications on histones are linked to cancer and developmental diseases. Characterizing the molecular mechanisms regulating these epigenetic ?on?/ ?off? pathways requires identification of new histone modification states, and development of new methodologies that permit comprehensive studies and unbiased screens of factors bound to distinct chromatin regions. To this end, we recently found a new histone modification, H3K23me3, using a specialized, entirely heterochromatic nucleus in the model organism Tetrahymena thermophila, and characterized it as a ?mark? of the pericentric chromatin that is important for maintaining genome integrity during meiosis. In this proposal, our goal is to follow up on our initial discovery by studying the enzymology associated with catalyzing and removing H3K23me3, as well as characterizing the biological role of this heterochromatin marker in humans and other mammals, where it may also be involved in neurogenesis. It is also worthwhile to note that we will comprehensively analyze the epiproteome of H3K23me3-associated chromatin in mammals using improvements on our new technology termed rCRISPR-ChAP-MS, which provides for the analysis of macromolecular protein interactions on chromatin at a defined genomic position in vivo. In doing so we will test the hypothesis that H3K23me3, through interactions with H3K23me3 binding proteins, helps to pinpoint, protect, and perpetuate sites of heterochromatin formation during meiosis and cell differentiation. To test our hypothesis and work towards our short term goal, we will pursue the following three Aims: (1) Characterize the enzymology and biological impact of H3K23me3 in Tetrahymena, (2) Characterize the role of H3K23me3 in mammalian meiosis, and (3) Characterize the role of H3K23me3 in mammalian neuronal development. Our study of the molecular underpinnings of how heterochromatic histone PTMs like H3K23me3 contribute to epigenetic silencing should help address our long term goal of understanding transgenerational inheritance of epigenetic modifiers, and may introduce therapeutic targets for human diseases associated with disrupted gene silencing or heterochromatin pathways.

Public Health Relevance

Since mis-regulation of chromatin structure and histones post-translational modifications is linked to cancer and other epigenetic diseases, it is imperative to characterize new histone PTM states, and establish new methodologies that permit comprehensive studies and unbiased screens for elucidating the epigenetic mechanisms controlling those modifications. We plan to follow up on our recent discovery of a new heterochromatic histone modification, H3K23me3, by studying the enzymology associated with catalyzing and removing H3K23me3, as well as by characterizing the biological role mammals, where it may be involved in maintaining genome integrity during meiosis and neuronal development. Furthermore, we will comprehensively analyze the epiproteome of H3K23me3-associated chromatin using our new ChAP-MS technology that provides for the analysis of macromolecular protein interactions on chromatin at a single defined genomic position in vivo, which will provide major insights for epigeneticists exploring mammalian genome instability, epigenetic disregulation, and possibly, transgenerational inheritance.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM118760-01A1
Application #
9239607
Study Section
Molecular Genetics B Study Section (MGB)
Program Officer
Carter, Anthony D
Project Start
2017-03-01
Project End
2021-01-31
Budget Start
2017-03-01
Budget End
2018-01-31
Support Year
1
Fiscal Year
2017
Total Cost
$387,783
Indirect Cost
$137,783
Name
Johns Hopkins University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bhat, Shridhar; Hwang, Yousang; Gibson, Matthew D et al. (2018) Hydrazide Mimics for Protein Lysine Acylation To Assess Nucleosome Dynamics and Deubiquitinase Action. J Am Chem Soc 140:9478-9485
Hartman, Jessica H; Miller, Grover P; Caro, Andres A et al. (2017) 1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice. Toxicology 378:114-124